CoChat
Sign Up
Cited by 132Fatty Acid Research and HealthParaoxonase enzyme and polymorphismsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia

Calabresi, Laura, Villa, Barbara, Canavesi, Monica, Sirtori, Cesare R, James, Richard W, Bernini, Franco, Franceschini, Guido·2004·Metabolism
DOI 10.1016/j.metabol.2003.09.007
Open this paper in CoChat — free account

Abstract

A remarkable reduction of plasma concentrations of high-density lipoproteins (HDL), especially of the HDL(2) subfraction, is one of the typical lipoprotein alterations found in patients with familial combined hyperlipidemia (FCHL). Fourteen FCHL patients received 4 capsules daily of Omacor (an omega-3 polyunsaturated fatty acid [omega3 FA] concentrate providing 1.88 g of eicosapentaenoic acid [EPA] and 1.48 g of docosahexaenoic acid [DHA] per day; Pronova Biocare, Oslo, Norway) or placebo for 8 weeks in a randomized, double-blind, crossover study. Plasma triglycerides were 44% lower, and LDL cholesterol and apoliporpotein (apo)B were 25% and 7% higher after Omacor than placebo. HDL cholesterol was higher (+8%) after Omacor than placebo, but this difference did not achieve statistical significance. Omacor caused a selective increase of the more buoyant HDL(2) subfraction; plasma HDL(2) cholesterol and total mass increased by 40% and 26%, respectively, whereas HDL(3) cholesterol and total mass decreased by 4% and 6%. Both HDL(2) and HDL(3) were enriched in cholesteryl esters and depleted of triglycerides after Omacor. No changes were observed in the plasma concentration of major HDL apolipoproteins, LpA-I and LpA-I:A-II particles, lecithin:cholesterol acyltransferase (LCAT), and cholesteryl ester transfer protein (CETP). The plasma concentration of the HDL-bound antioxidant enzyme paraoxonase increased by 10% after Omacor. Omacor may be helpful in correcting multiple lipoprotein abnormalities and reducing cardiovascular risk in FCHL patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2003.09.007

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 55 references

Cited by

Sorted by citations

Items 101–132 of 132

Related

See all

Metadata

Authors
Calabresi, L., Villa, B., Canavesi, M., Sirtori, C. R., James, R. W., Bernini, F., & Franceschini, G.
Affiliations
  • University of Milan (IT)
  • University Hospital of Geneva (CH)
  • University of Parma (IT)
Corresponding author
Franceschini, Guido
ORCID
Venue
Metabolism
Publisher
Elsevier BV
Published
2004-02
Volume
53
Issue
2
Pages
153-158
ISSN
0026-0495 (ISSN-L)
DOI
10.1016/j.metabol.2003.09.007
OpenAlex
W2155441427
Cited by
132
References
55
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 8 · 2018: 2 · 2017: 6 · 2016: 5 · 2015: 8 · 2014: 4 · 2013: 8 · 2012: 10
FWCI
10.80
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
omega-3 polyunsaturated fatty acids, Omacor, HDL2, HDL3 cholesterol, HDL subfractions, familial combined hyperlipidemia, eicosapentaenoic acid, docosahexaenoic acid, paraoxonase, HDL apolipoproteins, lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein, triglycerides, apolipoprotein B, cardiovascular risk
MeSH terms
Adult, Apolipoproteins A, Carrier Proteins, Docosahexaenoic Acids, Double-Blind Method, Electrophoresis, Polyacrylamide Gel, Female, Glycoproteins, Humans, Hyperlipidemias, Phosphatidylcholine-Sterol O-Acyltransferase, Cholesterol, HDL, Cholesterol, LDL, Male, Particle Size, Triglycerides, Ultracentrifugation, Fatty Acids, Omega-3, Cross-Over Studies, Aryldialkylphosphatase, Cholesterol Ester Transfer Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review